Benitec Biopharma (NASDAQ:BNTC) Coverage Initiated at SVB Leerink

SVB Leerink initiated coverage on shares of Benitec Biopharma (NASDAQ:BNTC) in a report released on Monday, MarketBeat reports. The firm issued an outperform rating and a $13.00 price objective on the biotechnology company’s stock.

BNTC has been the topic of several other reports. JMP Securities lifted their price target on Benitec Biopharma from $10.00 to $16.00 and gave the stock a market outperform rating in a research report on Monday, April 22nd. Piper Sandler assumed coverage on shares of Benitec Biopharma in a research report on Thursday, June 13th. They set an overweight rating and a $30.00 target price on the stock.

Benitec Biopharma Stock Performance

NASDAQ:BNTC opened at $9.13 on Monday. The firm has a market capitalization of $85.55 million, a PE ratio of -4.91 and a beta of 0.91. The company has a current ratio of 4.18, a quick ratio of 4.18 and a debt-to-equity ratio of 0.01. Benitec Biopharma has a 1 year low of $1.86 and a 1 year high of $10.88. The firm’s fifty day simple moving average is $8.36 and its 200 day simple moving average is $6.16.

Benitec Biopharma (NASDAQ:BNTC) last issued its quarterly earnings results on Monday, May 13th. The biotechnology company reported ($1.64) earnings per share (EPS) for the quarter. On average, sell-side analysts anticipate that Benitec Biopharma will post -6.56 EPS for the current year.

Institutional Trading of Benitec Biopharma

A hedge fund recently raised its stake in Benitec Biopharma stock. GAMMA Investing LLC lifted its position in Benitec Biopharma Inc. (NASDAQ:BNTC) by 53.0% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,438 shares of the biotechnology company’s stock after purchasing an additional 1,884 shares during the quarter. GAMMA Investing LLC owned 0.06% of Benitec Biopharma worth $38,000 at the end of the most recent reporting period. 52.19% of the stock is currently owned by hedge funds and other institutional investors.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.